无码欧美成人av天堂456软件,大胆日本熟妇XXXX,9277在线观看免费播放,4p三个男人让我爽了一夜

全、新、優(yōu)、品、好四大特點：

磷酸化細胞核因子NF-κB p65抗體費用 全：公司提供上萬種產(chǎn)品，涵蓋了生物試劑，elisa試劑盒，標(biāo)準(zhǔn)品，培養(yǎng)基，原裝耗材，抗體、培養(yǎng)基、ATCC細胞等，基本上各種科研所需產(chǎn)品在我司都能找到。

新：產(chǎn)品更新速度較快，基本上每周都有新產(chǎn)品出現(xiàn)。

優(yōu)：產(chǎn)品質(zhì)量好，投訴比較少。

好：我公司具有優(yōu)質(zhì)的技術(shù)團隊，產(chǎn)品一旦售出，實驗過程中遇到困難可提供在線技術(shù)咨詢。使您使用產(chǎn)品時沒有任何的后顧之憂。

磷酸化細胞核因子NF-κB p65抗體費用 英文名稱  Anti-Phospho-NFKB p65(Ser468)

中文名稱  磷酸化細胞核因子NF-κB p65抗體費用 

別    名 RELA(phospho S468); NFKBp65; NF-κBp65; p65 NF kappaB; p65 NFkB; NFKBp65; RELA; Transcription Factor p65; v rel avian reticuloendotheliosis viral oncogene homolog A (nuclear factor of kappa light polypeptide gene enhancer in B cells 3 (p65)); V Rel Avian Reticuloendotheliosis Viral Oncogene Homolog A; v rel reticuloendotheliosis viral oncogene homolog A (avian); v-rel reticuloendotheliosis viral oncogene homolog A; p65NFKB; Avian reticuloendotheliosis viral (v rel) oncogene homolog A; MGC131774; NFKB 3; NFKB3; Nuclear Factor NF Kappa B p65 Subunit; Nuclear factor of kappa light polypeptide gene enhancer in B cells 3; Nuclear Factor Of Kappa Light Polypeptide Gene Enhancer In B Cells.

產(chǎn)品屬性：

濃    度  1mg/1ml

規(guī) 格  0.1ml/100μg

抗體來源  Rabbit

克隆類型   polyclonal

交叉反應(yīng)   Human, Mouse, Rat, Dog, Pig, Cow, Horse

產(chǎn)品類型   一抗 磷酸化抗體  

研究領(lǐng)域     細胞生物 免疫學(xué) 信號轉(zhuǎn)導(dǎo) 細胞凋亡 轉(zhuǎn)錄調(diào)節(jié)因子 激酶和磷酸酶 通道蛋白

蛋白分子量  predicted molecular weight: 61kDa 

性    狀   Lyophilized or Liquid

免 疫 原  KLH conjugated Synthesised phosphopeptide derived from human NFKBp65 around the phosphorylation site of Ser468

亞    型  IgG

純化方法   affinity purified by Protein A

儲 存 液   0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide

磷酸化細胞核因子NF-κB p65抗體費用 產(chǎn)品應(yīng)用   WB=1:100-200 IHC-P=1:100-200 IHC-F=1:100-200 IF=1:100-200

（石蠟切片需做抗原修復(fù)） 

 not yet tested in other applications.

 optimal dilutions/concentrations should be determined by the end user.  

保存條件  Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. 

Important Note  This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 

產(chǎn)品介紹 NF-kappa-B is a ubiquitous transcription factor involved in several biological processes. It is held in the cytoplasm in an inactive state by specific inhibitors. Upon degradation of the inhibitor, NF-kappa-B moves to the nucleus and activates transcription of specific genes. NF-kappa-B is composed of NFKB1 or NFKB2 bound to either REL, RELA, or RELB. The most abundant form of NF-kappa-B is NFKB1 complexed with the product of this gene, RELA. Four transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2011].

Function : NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and p65-c-Rel complexes are transcriptional activators. The NF-kappa-B p65-p65 complex appears to be involved in invasin-mediated activation of IL-8 expression. The inhibitory effect of I-kappa-B upon NF-kappa-B the cytoplasm is exerted primarily through the interaction with p65. p65 shows a weak DNA-binding site which could contribute directly to DNA binding in the NF-kappa-B complex. Associates with chromatin at the NF-kappa-B promoter region via association with DDX1.Subunit : Component of the NF-kappa-B p65-p50 complex. Component of the NF-kappa-B p65-c-Rel complex. Homodimer; component of the NF-kappa-B p65-p65 complex. Component of the NF-kappa-B p65-p52 complex. May interact with ETHE1. Binds AES and TLE1. Interacts with TP53BP2. Binds to and is phosphorylated by the activated form of either RPS6KA4 or RPS6KA5. Interacts with ING4 and this interaction may be indirect. Interacts with CARM1, USP48 and UNC5CL. Interacts with IRAK1BP1 (By similarity). Interacts with NFKBID (By similarity). Interacts with NFKBIA. Interacts with GSK3B. Interacts with NFKBIB (By similarity). Interacts with NFKBIE. Interacts with NFKBIZ. Interacts with EHMT1 (via ANK repeats) (By similarity). Part of a 70-90 kDa complex at least consisting of CHUK, IKBKB, NFKBIA, RELA, IKBKAP and MAP3K14. Interacts with HDAC3; HDAC3 mediates the deacetylation of RELA. Interacts with HDAC1; the interaction requires non-phosphorylated RELA. Interacts with CBP; the interaction requires phosphorylated RELA. Interacts (phosphorylated at 'Thr-254') with PIN1; the interaction inhibits p65 binding to NFKBIA. Interacts with SOCS1. Interacts with UXT. Interacts with MTDH and PHF11. Interacts with ARRB2. Interacts with human respiratory syncytial virus (HRSV) protein M2-1. Interacts with NFKBIA (when phosphorylated), the interaction is direct; phosphorylated NFKBIA is part of a SCF(BTRC)-like complex lacking CUL1. Interacts with RNF25. Interacts (via C-terminus) with DDX1. Interacts with UFL1 and COMMD1. Interacts with BRMS1; this promotes deacetylation of 'Lys-310'. Interacts with NOTCH2 (By similarity). Directly interacts with MEN1; this interaction represses NFKB-mediated transactivation. Interacts with AKIP1, which promotes the phosphorylation and nuclear retention of RELA. Interacts (via the RHD) with GFI1; the interaction, after bacterial lipopolysaccharide (LPS) stimulation, inhibits the transcriptional activity by interfering with the DNA-binding activity to target gene promoter DNA.Subcellular Location : Nucleus. Cytoplasm. Note=Colocalized with DDX1 in the nucleus upon TNF-alpha induction. Nuclear, but also found in the cytoplasm in an inactive form complexed to an inhibitor (I-kappa-B). Colocalizes with GFI1 in the nucleus after LPS stimulation.Post-translational modifications : Ubiquitinated, leading to its proteasomal degradation. Degradation is required for termination of NF-kappa-B response.Monomethylated at Lys-310 by SETD6. Monomethylation at Lys-310 is recognized by the ANK repeats of EHMT1 and promotes the formation of repressed chromatin at target genes, leading to down-regulation of NF-kappa-B transcription factor activity. Phosphorylation at Ser-311 disrupts the interaction with EHMT1 without preventing monomethylation at Lys-310 and relieves the repression of target genes.Phosphorylation at Ser-311 disrupts the interaction with EHMT1 and promotes transcription factor activity. Phosphorylation on Ser-536 stimulates acetylation on Lys-310 and interaction with CBP; the phosphorylated and acetylated forms show enhanced transcriptional activity. Phosphorylation at Ser-276 by RPS6KA4 and RPS6KA5 promotes its transactivation and transcriptional activities.Reversibly acetylated; the acetylation seems to be mediated by CBP, the deacetylation by HDAC3 and SIRT2. Acetylation at Lys-122 enhances DNA binding and impairs association with NFKBIA. Acetylation at Lys-310 is required for full transcriptional activity in the absence of effects on DNA binding and NFKBIA association. Acetylation can also lower DNA-binding and results in nuclear export. Interaction with BRMS1 promotes deacetylation of Lys-310. Lys-310 is deacetylated by SIRT2.S-nitrosylation of Cys-38 inactivates the enzyme activity.Sulfhydration at Cys-38 mediates the anti-apoptotic activity by promoting the interaction with RPS3 and activating the transcription factor activity.Sumoylation by PIAS3 negatively regulates DNA-bound activated NF-kappa-B.Similarity : Contains 1 RHD (Rel-like) domain.Database links : UniProtKB/Swiss-Prot: Q04206.2轉(zhuǎn)錄調(diào)節(jié)因子（Transcriptin Regulators） NF-κBp65是一種重要的轉(zhuǎn)錄因子，NF-kBp65可激活參與、細胞增殖、細胞凋亡等基因的調(diào)節(jié)，影響著細胞的凋亡，同時影響著細胞對細胞毒性藥物及離子輻射的敏感性。ras基因誘導(dǎo)的致癌突變作用需NFkB的活化，提示NFkB在致癌發(fā)生方面可能起一定作用；另有文獻報道，在、非小細胞性、、T或B淋巴細胞及誘變導(dǎo)致的等人類中，NFkB活化或表達。經(jīng)研究認(rèn)為：NFKBp65蛋白在靜息狀態(tài)下以結(jié)合態(tài)的方式存在于胞漿中，當(dāng)NFKBp65蛋白被激活后解離進入細胞核。 NF-кB可以保護細胞免受以及電離輻射等引起的凋亡作用，而抑制NFkB的表達可以增加TNF等引起的細胞凋亡，以及增加及對細胞的敏感性。

實驗流程：

正在熱銷的相關(guān)產(chǎn)品：

integrin Beta1(ITG- Beta1/CD29) 粘附分子整合素β1抗原Multi-class antibodies規(guī)格： 0.5mg

Anti-ADRA2 ADRA2能受體2抗體Multi-class antibodies規(guī)格： 0.2ml

Rhesus antibody Rh phospho-CD19(Ser227) 磷酸化CD19抗體 規(guī)格 0.1ml

TMB雙組分A+B液 AB液各500ml 用于ELISA

VGLL2 英文名稱： 轉(zhuǎn)錄輔助因子退變樣蛋白2抗體 0.2ml

Dnmt2 英文名稱： DNA甲基轉(zhuǎn)移酶2抗體 0.2ml

Anti-ADRA2 ADRA2能受體2抗體Multi-class antibodies規(guī)格： 0.2ml

pre S1/S2 protein [HBV] 乙毒pre S1/乙毒pre S2(抗原)Multi-class antibodies規(guī)格： 0.5mg

Anti-CD147/TCSF 細胞外基質(zhì)金屬蛋白酶誘導(dǎo)因子抗體Multi-class antibodies規(guī)格： 0.1ml

Rhesus antibody Rh P* 缺陷性分配同源物α抗體 規(guī)格 0.2ml

CD38 Kit Human 人 SCARB3 ELISA配對抗體 ELISA

TLR6 英文名稱： Toll樣受體6抗體 0.1ml

CDK4 英文名稱： 周期素依賴性激酶4抗體 0.1ml

Anti-CD147/TCSF 細胞外基質(zhì)金屬蛋白酶誘導(dǎo)因子抗體Multi-class antibodies規(guī)格： 0.1ml

L-Selectin/CD62L ELISA Kit 小鼠L選擇素Multi-class antibodies規(guī)格： 48T

Anti-BECN1/FITC 熒光素標(biāo)記一種基因抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Rhesus antibody Rh ERG25 甲基固醇羥化酶單加氧酶1抗體 規(guī)格 0.2ml

NOS (Rabbit nitric oxide synthase) ELISA Kit 兔合成酶 96T

MYH9 英文名稱： 肌球蛋白重鏈9抗體 0.2ml

AKIRIN1 英文名稱： AKIRIN1蛋白抗體 0.1ml

Anti-BECN1/FITC 熒光素標(biāo)記一種基因抗體IgGMulti-class antibodies規(guī)格： 0.2ml

壞死因子

Calu-6 人退行性癌細胞

CC Others Human 人 CC / chymoypsin C 人細胞裂解液 (陽性對照)

PANC-1人*癌細胞 Human pancreatic cancer cell line PANC-1 DMEM+10% FBS

小鼠細胞;P388D1(IL-1)

人主動脈內(nèi)皮細胞 (HAEC)( 5×105 ) BRL 3A, 大鼠肝正常細胞 Rattus

CL-0464USMC(大鼠平滑肌細胞)5×106cells/瓶×2

CD44 Others Human 人 CD44 人細胞裂解液 (陽性對照)

人肝內(nèi)膽管上皮細胞RNAHIBEpiC miRNA5 μg

5637(HTB-9)細胞，人細胞 大鼠細胞(癌細胞接種到*成瘤),Walker-256細胞 MLF, 小鼠淋巴成纖維細胞

HO-8910PM(人高轉(zhuǎn)移細胞) 5×106cells/瓶×2

hMSC-AT-c 人類脂肪組織間質(zhì)干細胞(hMSC-AT) 500,000cells 小鼠背脊髓神經(jīng)元MN-dsc

磷酸化細胞核因子NF-κB p65抗體費用 壞死因子

Calu-6 人退行性癌細胞

CC Others Human 人 CC / chymoypsin C 人細胞裂解液 (陽性對照)

PANC-1人*癌細胞 Human pancreatic cancer cell line PANC-1 DMEM+10% FBS

小鼠細胞;P388D1(IL-1)

人主動脈內(nèi)皮細胞 (HAEC)( 5×105 ) BRL 3A, 大鼠肝正常細胞 Rattus

技術(shù)外包服務(wù):

★磷酸化細胞核因子NF-κB p65抗體費用 分子生物學(xué)：質(zhì)粒抽提、PCR、Q-PCR、RT-PCR、分子生物學(xué)：基因合成、引物合成、基因測序、載體構(gòu)建等

★蛋白工程：原核、哺乳動物蛋白表達系統(tǒng)等

★病毒包裝：腺病毒、慢病毒等

★抗體工程：磁珠分選、病理染色、WB、ELISA、IP、IF、IHC、FACS、Confocal等等

★細胞工程：細胞表型分析(凋亡、增殖、周期、遷移、侵襲、修復(fù)、克隆形成)、細胞培養(yǎng)、細胞膜制備、穩(wěn)定細胞株構(gòu)建、細胞RNAi技術(shù)等等。